Home › Research › Inflammation and the immune system
Minocycline for sporadic and hereditary cerebral amyloid angiopathy (BATMAN): study protocol for a placebo-controlled randomized double-blind trial
Voigt S, Koemans EA, Rasing I, van Etten ES, Terwindt GM, Baas F, Kaushik K, van Es ACGM et al.. Trials, 2023-06-05
Topic: Brain proteins, microglia and lab models
Plain-language summary
Background Cerebral amyloid angiopathy (CAA) is a disease caused by the accumulation of the amyloid-beta protein and is a major cause of intracerebral hemorrhage (ICH) and vascular dementia in the elderly. The presence of the amyloid-beta protein in the vessel wall may induce a chronic state of cerebral inflammation by activating astrocytes, microglia, and pro-inflammatory substances. Minocycline, an antibiotic of the tetracycline family, is known to modulate inflammation, gelatinase activity, and angiogenesis. These processes are suggested to be key mechanisms in CAA pathology. Our aim is to show the target engagement of minocycline and investigate in a double-blind placebo-controlled randomized clinical trial whether treatment with minocycline for 3 months can decrease markers of neuroinflammation and of the gelatinase pathway in cerebrospinal fluid (CSF) in CAA patients. Methods The BATMAN study population consists of 60 persons: 30 persons with hereditary Dutch type CAA (D-CAA) and 30 persons with sporadic CAA. They will be randomized for either placebo or minocycline (15 sporadic CAA/15 D-CAA minocycline, 15 sporadic CAA/15 D-CAA placebo). At t = 0 and t = 3 months, we will collect CSF and blood samples, perform a 7-T MRI, and collect demographic characteristics. Discussion The results of this proof-of-principle study will be used to assess the potential of target engagement of minocycline for CAA. Therefore, our primary outcome measures are markers of neuroinflammation (IL-6, MCP-1, and IBA-1) and of the gelatinase pathway (MMP2/9 and VEGF) in CSF. Secondly, we will look at the progression of hemorrhagic markers on 7-T MRI before and after treatment and investigate serum biomarkers. Trial registration ClinicalTrials.gov NCT05680389. Registered on January 11, 2023.
What this study adds
Evidence grade: High
The record lists 60 participants. This paper describes the plan for the BATMAN trial, which will give minocycline, an antibiotic known to affect inflammation, or a placebo for 3 months to 60 people with hereditary or sporadic cerebral amyloid angiopathy, where amyloid builds up in brain blood vessels. The main goal is to see whether the drug lowers inflammation markers in spinal fluid.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Voigt, S., Koemans, E. A., Rasing, I., van Etten, E. S., Terwindt, G. M., Baas, F., et al. (2023). Minocycline for sporadic and hereditary cerebral amyloid angiopathy (BATMAN): study protocol for a placebo-controlled randomized double-blind trial. Trials. https://doi.org/10.1186/s13063-023-07371-4
Vancouver
Voigt S, Koemans EA, Rasing I, van Etten ES, Terwindt GM, Baas F, et al. Minocycline for sporadic and hereditary cerebral amyloid angiopathy (BATMAN): study protocol for a placebo-controlled randomized double-blind trial. Trials. 2023. doi:10.1186/s13063-023-07371-4. PMID: 37277877.
BibTeX
@article{voigt2023-37277877,
author = {Voigt, S. and Koemans, E. A. and Rasing, I. and van Etten, E. S. and Terwindt, G. M. and Baas, F. and Kaushik, K. and van Es, A. C. G. M. and others},
title = {{Minocycline for sporadic and hereditary cerebral amyloid angiopathy (BATMAN): study protocol for a placebo-controlled randomized double-blind trial}},
journal = {Trials},
year = {2023},
doi = {10.1186/s13063-023-07371-4},
pmid = {37277877},
url = {https://doi.org/10.1186/s13063-023-07371-4}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Discussion The results of this proof-of-principle study will be used to assess the potential of target engagement of minocycline for CAA.
Why it matters
This paper describes the plan for the BATMAN trial, which will give minocycline, an antibiotic known to affect inflammation, or a placebo for 3 months to 60 people with hereditary or sporadic cerebral amyloid angiopathy, where amyloid builds up in brain blood vessels. The main goal is to see whether the drug lowers inflammation markers in spinal fluid. It is a design paper, so no results are reported in this record.
Study details
- Participants60
- Evidence strengthHigh
How this study scored 53/100
Published in a peer-reviewed journal. Scored zero for study design and effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Trials) |
| Journal's citation record | 1 / 4 | Trials: journal h-index 132 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 60 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 3 / 7 | Cited 19 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.8 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 2 / 6 | Cited 2.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 4 other studies in this library |
| Still being cited | 2 / 4 | Cited 19 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Marieke J.H. Wermer: h-index 67 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Radboud University Nijmegen: institution h-index 1,143 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37277877) |
| Free to read | 2 / 2 | Free to read |
| Total | 53 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
4 studies in the alzhub library list this one in their references.
Related studies in Inflammation and the immune system from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.